Sinovac Launches Phase 3 COVID-19 Vaccine Trial in Turkey
Sinovac Biotech has launched a phase 3 clinical trial to assess the safety and efficacy of its COVID-19 vaccine candidate in Turkey.
Participants ages 18-59 will be given either two doses of CoronaVac or a placebo at a two-week interval. The first stage of the study will enroll 1,300 healthcare workers and the second stage will enroll 12,000 members of the general population.
CoronaVac received emergency approval in China in July for vaccination of high-risk populations, such as medical staff and frontline pandemic workers. It is also in phase 3 testing in Indonesia and Brazil.